ADMA BIOLOGICS INC - COMMON STOCK

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance

17 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®

13 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

09 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

07 Dec 2022 08:45:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Proposed Public Offering of Common Stock

06 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate

06 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update

09 Nov 2022 16:05:02 By Nasdaq GlobeNewswire

ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

02 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC

31 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update

10 Aug 2022 16:05:01 By Nasdaq GlobeNewswire

ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

ADMA Biologics Announces Addition to the Russell 2000® Index

21 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update

11 May 2022 16:05:01 By Nasdaq GlobeNewswire

ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022

04 May 2022 07:00:01 By Nasdaq GlobeNewswire

ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022

01 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months

25 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management

24 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

21 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA

07 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update

19 Jan 2022 07:00:00 By Nasdaq GlobeNewswire